DUBLIN, Jan. 14, 2016 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/8hhl4b/colorectal_cancer) has announced the addition of the "Colorectal Cancer Therapeutics Market in APAC 2015-2019" report to their offering.
The colorectal cancer therapeutics market in APAC to grow at a CAGR of 6.32% over the period 2014-2019.
The report covers the current scenario and the growth prospects of the colorectal cancer therapeutics market in APAC for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment of colorectal cancer. The colorectal cancer therapeutics market in APAC is segmented based on lines of chemotherapy: first-line chemotherapy and second-line chemotherapy.
The report, Colorectal Cancer Therapeutics Market in APAC 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers APAC; it also covers the landscape of the colorectal cancer therapeutics market in APAC and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Biologics are one of the treatment choices for colorectal cancer. These are targeted therapies, which act only on the malignant cells and do not destroy the healthy cells. Biologics that are used for treating colorectal cancer include Avastin (bevacizumab), Erbitux (cetuximab), Vectibix (panitumumab) and Zaltrap (ziv-Aflibercept). These drugs together accounted for the major share of the market, and the same trend is expected to continue during the forecast period.
According to the report, many drug makers assist patients financially and enable access to medicines. Patient access programs are designed to fit the needs of individuals with colorectal cancer. For instance, Sanofi's "Sanofi Patient Connection" program aims to increase access to Zaltrap by providing free prescription medications and financial assistance. Bayer has introduced "Stivarga Reach Program" to provide co-pay assistance to patients. F. Hoffmann-La Roche's "Genentech Access Solutions" is another such program that covers the treatment expenses of patients using Avastin, or provides reimbursement support or co-pay assistance, if the patients fulfill certain criteria.
Further, the report states that the high cost of treatment of colorectal cancer is a major challenge the colorectal cancer therapeutics market in APAC is expected to experience during the forecast period.
- Bristol-Myers Squibb
- Chugai Pharmaceuticals
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Product profiles
Part 04: Market research methodology
Part 05: Introduction
Part 06: Disease overview
Part 07: Pipeline portfolio
Part 08: Market landscape
Part 09: Market segmentation by based on the type of molecules
Part 10: Market segmentation by route of administration
Part 11: Market segmentation by lines of chemotherapy
Part 12: Market drivers
Part 13: Impact of drivers
Part 14: Market challenges
Part 15: Impact of drivers and challenges
Part 16: Market trends
Part 17: Vendor landscape
Part 18: Key vendor analysis
For more information visit
Laura Wood, +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets